Cancer Treatment Pioneer Dr. Andrew Pecora of John Theurer Cancer Center Joins Vice President's DC Moonshot Summit, Unprecedented National Effort to End Cancer

HACKENSACK, N.J., June 30, 2016 /PRNewswire/ --

WHAT:   Advances in research, molecular therapy, precision medicine, genomics and the use of patient data to guide treatment have brought the dream of defeating cancer closer to reality, and Vice President Biden's national Cancer Moonshot Summit held yesterday across the nation provides the inspiration and motivation necessary to achieve that goal.

Andrew Pecora, MD, FACP, CPE, Chief Innovation Officer Professor and Vice President of Cancer Services, John Theurer Cancer Center, is available for media interviews to provide his unique perspective on the Moonshot initiative and discuss the role of John Theurer Cancer Center and Hackensack University Medical Center in advancing the goals of this unprecedented initiative.

WHO:   Dr. Pecora, who attended yesterday's White House-sponsored Summit in Washington, DC to accelerate cancer research, is widely acknowledged as one of the world's leading experts in blood and marrow stem cell transplantation, cellular medicine and immunology research. He has also been a leader in the establishment of Cancer Outcomes Tracking Analysis, known as COTA, a technology platform that improves clinical outcomes and reduces wasteful spend in oncology through precise classification of illness and a smarter use of data.

According to Dr. Pecora:

"Clinical, research and technology advances, along with commitment and collaboration from academia, industry, advocacy and government make the goal of ending cancer as we know it more possible than ever."

"The potential of the combination of data – used and interpreted wisely – molecular therapies, precision medicine and advanced technology vastly improves our ability to extend and save lives, and bring us closer to the goal of achieving achieve cure."

"As one of the largest centers of cancer care in the nation, we are engaged in many of the leading immunotherapy combination therapy trials that are built around a collaborative model of innovation.  John Theurer Cancer Center is often among the 'first-to-enroll' centers that will unlock tomorrow's innovative treatments."

WHEN:   July 5-8, 2016

About John Theurer Cancer Center at Hackensack University Medical Center
John Theurer Cancer Center is New Jersey's largest and most comprehensive cancer center dedicated to the diagnosis, treatment, management, research, screenings, preventive care and survivorship of patients with all types of cancer. Each year, more people in the New Jersey/New York metropolitan area turn to John Theurer Cancer Center for cancer care than to any other facility in New Jersey. The 14 specialized divisions feature a team of medical, research, nursing and support staff with specialized expertise that translates into more advanced, focused care for all patients. John Theurer Cancer Center provides comprehensive multidisciplinary care, state of the art technology, and access to clinical trials, compassionate care and medical expertise— all under one roof. For more information please visit www.jtcancercenter.org.

SOURCE John Theurer Cancer Center at Hackensack University Medical Center

Related Links

http://www.jtcancercenter.org